BMS-641988

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H20F3N3O5S
Molecular Weight	471.45
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12C(=O)N(C(=O)[C@@]1([H])[C@@]3(C)O[C@]2(C)C[C@H]3NS(=O)(=O)CC)C4=CC=C(C#N)C(=C4)C(F)(F)F

InChI

InChIKey=HYNANJUKEMCYEQ-HIGHGGLBSA-N

InChI=1S/C20H20F3N3O5S/c1-4-32(29,30)25-13-8-18(2)14-15(19(13,3)31-18)17(28)26(16(14)27)11-6-5-10(9-24)12(7-11)20(21,22)23/h5-7,13-15,25H,4,8H2,1-3H3/t13-,14-,15+,18-,19+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C20H20F3N3O5S
Molecular Weight	471.45
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19654297 | https://www.ncbi.nlm.nih.gov/pubmed/26288692

Bristol-Myers Squibb developed BMS-641988 as a nonsteroidal androgen receptor antagonist for the treatment of prostate cancer. BMS-641988 participated in phase I clinical trials in patients with castration-resistant prostate cancer in Japan and in the USA. However, further information is not available.

Originator

Approval Year

PubMed

Title	Date	PubMed
Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening.	2011 Sep 22	21846139

Sample Use Guides

In Vivo Use Guide

Drug: BMS-641988 (AR#2) Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 04:40:31 UTC 2023` Edited by `admin` on `Sat Dec 16 04:40:31 UTC 2023`
Record UNII	W17M53Y8IM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BMS-641988

Common Name

English

BMS 641988 [WHO-DD]

Common Name

English

ETHANESULFONAMIDE, N-((3AR,4R,5R,7R,7AS)-2-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)OCTAHYDRO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-1H-ISOINDOL-5-YL)-

Systematic Name

English

Code System Code Type Description

FDA UNII

W17M53Y8IM